Related Experiment Video
Updated: Jan 1, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Barriers to hepatitis C virus treatment in Guangdong Province
Xiaohua Yang1, Zhen Xu1, Yongyu Mei1
1Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Insights
Many hepatitis C virus (HCV) patients in Guangdong do not receive antiviral therapy (AVT) due to cost, fear of side effects, and medical contraindications. Addressing these barriers is key to increasing HCV cure rates.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) infection remains a significant public health concern.
- Chronic HCV infection requires effective antiviral therapy (AVT) to prevent severe liver disease.
- Increasing HCV cure rates is a primary goal in Guangdong Province.
Purpose of the Study:
- To analyze the reasons for non-treatment among HCV-infected patients.
- To identify barriers to accessing antiviral therapy (AVT) for chronic hepatitis C.
- To inform strategies for improving HCV treatment rates in Guangdong Province.
Main Methods:
- A retrospective and prospective study was conducted.
- The study cohort comprised 435 outpatients diagnosed with HCV infection.
- Subjective and objective causes of non-treatment were analyzed.
Main Results:
- Out of 1,931 patients, 435 did not receive AVT.
- Key reasons for non-treatment included economic constraints (17.7%), patient fears (10.6%), fertility concerns (8.5%), and dosing inconvenience (2.1%).
- Medical contraindications were prevalent (31.5%), including decompensated hepatic cirrhosis (12.6%), alcoholism (3.4%), and drug addiction (7.1%).
Conclusions:
- HCV non-treatment is multifactorial, influenced by patient-related and medical factors.
- Economic constraints and patient apprehension regarding side effects are significant barriers to AVT.
- Medical contraindications, such as advanced liver disease and substance abuse, also limit treatment access.
Background:
The objective of this study is to analyze the causes of nontreatment among patients with hepatitis C virus (HCV) infection and increase the cure rate of chronic hepatitis C in Guangdong Province.
Methods:
We performed both retrospective survey and prospective study in a cohort of 435 outpatients in our center to analyze the subjective and objective causes of HCV non-treatment.
Results:
Among 1,931 patients, 435 did not receive anti-viral therapy (AVT), and, in 37 of these patients, the virus load was persistently negative. In the remaining 398 patients, HCV RNA repeatedly tested positive. The causes of nontreatment in these patients included economic constraints (n=77, 17.7%); old age, fear of treatment-related side effects, uncertainty (n=46, 10.6%); fear of potential adverse effects on fertility (n=37, 8.5%); fear of interferon side-effects (n=21, 4.8%); and dosing inconvenience during study or work (n=9, 2.1%). In addition, 137 patients (31.5%) had medical contraindications including decompensated hepatic cirrhosis (n=55, 12.6%), uncontrolled autoimmune diseases (e.g., autoimmune hepatitis and systemic lupus erythematosus) (n=19, 4.4%), renal dysfunction (n=21, 4.8%), thyroid disease (hyperthyroidism) (n=16, 3.7%), depression (n=14, 3.2%), uncontrolled diabetes (n=5, 1.1%), severe lung disease (e.g., active tuberculosis) (n=4, 0.9%), symptomatic heart disease (n=3, 0.7%), alcoholism (n=15, 3.4%), drug addiction (n=31, 7.1%), lack of physician recommendation (n=2, 0.5%), and unknown reasons (n=23, 5.3%).
Conclusions:
The low rate of AVT in HCV-infected patients is related to many factors. In Guangdong province, HCV patients do not receive AVT mainly due to economic constraints, patients' fear of side effects, and the presence of contraindications.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022